A successful partnership between the APHM Pathology department / the GlioME team and ID-Solutions industrial society (https://www.id-solutions.fr/fr/), has led to the developement of ready-to-use kits for the detection and quantification by digital PCR of key genetic alterations of brain tumours, specifically gliomas.
The paper that has just been published in Frontiers in Oncology reports on the usefulness of five multiplexed digital PCR assays to quickly, easily and simultaneously assess the status of several biomarkers by using small amounts of DNA extracted from fixed tissue. Two tests are dedicated to low-grade pediatric tumours, targeting the BRAF and FGFR1 genes and the others are useful for the diagnosis of high-grade infiltrating tumours by targeting alterations in the IDH1/2, H3F3A and TERT promoter genes.
These kits are now commercialy available (https://www.id-solutions.fr/fr/kits-de-detection-2/) and are routinely used in the APHM Pathology department, allowing quick and accurate molecular diagnoses, essential for patient care.
